Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2021-03-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
2020年年度审计报告
Regulatory Filings
2021-03-29 Chinese
2020年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2020 年年度报告摘要" which translates to "2020 Annual Report Summary". It contains detailed financial data for the year 2020, including revenue, net profit, earnings per share, and other financial indicators. It also discusses business operations, management changes, accounting policies, and other comprehensive information typical of an annual report. The document length is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. There is no indication that this is merely a notice of report publication or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-03-29 Chinese
年度募集资金使用情况专项说明
Capital/Financing Update Classification · 95% confidence The document is titled as a special report from the board of directors regarding the storage and usage of raised funds for the fiscal year 2020. It details the amount of funds raised, their allocation, usage over multiple years including 2020, and the management and regulatory compliance related to these funds. It includes detailed tables on fund usage, investment projects, and cash management of idle funds. There is also an auditor's verification opinion and a sponsor's verification opinion confirming compliance with regulatory requirements. The document is focused on the usage and management of capital raised by the company, specifically the raised funds and their deployment, which aligns with the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or other types of filings. The length and detail confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-03-29 Chinese
监事会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding multiple reports and proposals related to the fiscal year 2020, including the Supervisory Board Work Report, the 2020 Annual Report, the 2020 Financial Final Report, profit distribution plan, internal control evaluation report, and special report on the use of raised funds. It also includes voting results on these matters. The document is relatively short (2738 characters) and primarily announces the approval of these reports and proposals, with references to the full reports being available elsewhere (e.g., on the cninfo website). This fits the pattern of a Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the outcomes of votes on key company reports and proposals at a Supervisory Board meeting, some of which require further shareholder approval. It is not the full Annual Report (10-K) or the full financial statements themselves, but an announcement of resolutions and voting results related to these reports. Therefore, the correct classification is DVA with high confidence.
2021-03-29 Chinese
关于全资子公司取得《药品生产许可证》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 启迪药业集团股份公司 regarding its wholly-owned subsidiary obtaining a new pharmaceutical production license issued by the Hunan Provincial Drug Administration. It details the license information, production scope, and the impact on the company. The document is short (1035 characters) and serves as an official announcement of a regulatory approval rather than a financial report or detailed operational report. It does not contain financial data, management discussion, or detailed report content. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about compliance and licensing.
2021-03-22 Chinese
2020年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2020 annual earnings forecast (业绩预告) from 启迪药业集团股份公司, covering the period from January 1, 2020 to December 31, 2020. It provides preliminary estimated financial results such as net profit and earnings per share, with explanations for the changes and a risk warning. The document explicitly states that the data are preliminary, unaudited, and that the audited results will be disclosed in the 2020 annual report. The document length is short (1032 characters), and it is clearly an earnings forecast rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a report publication announcement (RPA) or regulatory filing (RNS). Therefore, the correct classification is Earnings Release (ER). FY 2020
2021-01-29 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.